Ezlopitant

Ezlopitant
Clinical data
Other names	CJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine
Routes of; administration	By mouth
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Pharmacokinetic data
Excretion	Urine (32%), Feces (51%)
Identifiers
	IUPAC name (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine;
CAS Number	147116-64-1;
PubChem CID	188927;
IUPHAR/BPS	5751;
ChemSpider	164166;
UNII	3L098A8MPY;
ChEMBL	ChEMBL515966;
CompTox Dashboard (EPA)	DTXSID601318557 ;
Chemical and physical data
Formula	C31H38N2O
Molar mass	454.658 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C;
	InChI InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1; Key:XPNMCDYOYIKVGB-CONSDPRKSA-N;

Ezlopitant (INN,^[1] code name CJ-11,974) is an NK₁ receptor antagonist.^[2]^[3]^[4] It has antiemetic and antinociceptive effects.^[5]^[6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.^[2]

Quick facts Clinical data, Other names ...

See also